Meeting
2024 ASCO Annual Meeting
Clinical outcomes of NOTCH pathway-activated adenoid cystic carcinoma with and without co-occurrent TP53 mutation.
Authors
Syeda Malaika Haider
Macclesfield District General Hospital, Macclesfield, United Kingdom
Syeda Malaika Haider , Joseph Edward Haigh , Karan Patel , Samuel Rack , Laura Spurgeon , Guy Betts , Kevin Joseph Harrington , Robert Metcalf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 6101)
DOI
10.1200/JCO.2024.42.16_suppl.6101
Abstract #
6101
Poster Bd #
417
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
ELLA01-1: A study to determine the utility of TP53 mutations as a prognostic biomarker in adenoid cystic carcinoma.
First Author: Robert Metcalf
Poster
2023 ASCO Annual Meeting
Predictive biomarkers of benefit to axitinib plus avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).
First Author: Camilla Oliveira Hoff
Poster
2023 ASCO Annual Meeting
Clinical and genomic characterisation of adenoid cystic carcinoma of the head and neck, lung, and breast.
First Author: Emily Heathcote
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Concordance in oncogenic alterations between primary and recurrent/metastatic cholangiocarcinoma pairs using targeted next-generation sequencing.
First Author: Sarah Margaret Helena McIntyre